MedTrace Logo

Mangafodipir as an Adjunct to Percutaneous Coronary Intervention

NCT00966563 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2013-07-16

No results posted yet for this study

Summary

The present feasibility study is designed to find out whether pre-treatment with the compound mangafodipir (PP-099) provides an additional reduction in myocardial infarct size in patients treated with primary percutaneous coronary intervention (PCI) during acute myocardial infarction (AMI).

Conditions

Interventions

DRUG

Mangafodipir

Administered dose: 2 µmol/kg b.w. Administration form: Ready-to-use formulation (solution). Mangafodipir or placebo (0.2 ml/kg b.w.) will be administered as an intravenous (iv.) infusion over 2-5 min prior to reopening of occluded coronary artery during PCI

DRUG

Placebo

Sponsors & Collaborators

  • Egetis Therapeutics

    lead INDUSTRY

Principal Investigators

  • Jan-Erik Karlsson, MD, PhD · Department of Internal Medicine, County Hospital Ryhov, SE-551 85 Jönköping, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2013-05-31
Completion
2013-07-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00966563 on ClinicalTrials.gov